Opportunities / ENERGY, DEPARTMENT OF
TECHNOLOGY LICENSING OPPORTUNITY: Clathrate Therapeutics Platform
Free · see which open contracts fit your company, with due dates and past-award prices. Sample report →
| Notice type | Special Notice |
|---|---|
| Solicitation # | S-195396 |
| Department | ENERGY, DEPARTMENT OF |
| Sub-tier / office | ENERGY, DEPARTMENT OF / TRIAD - DOE CONTRACTOR |
| NAICS | 325412 — Pharmaceutical Preparation Manufacturing |
| PSC | 6505 |
| Set-aside | No set-aside |
| Posted | Jun 4, 2026 |
| Response deadline | Dec 4, 2026 (2026-12-03T17:00:00-07:00) |
| Place of performance | Los Alamos, NM, 87545 |
| Primary contact | Caleb Ledgerwood · licensing@lanl.gov |
🔔 Get notices like this every morning
New matching SAM.gov notices every morning by Telegram or email. No UEI, no password · 14-day Solo trial, no card.
Registered in SAM.gov? Use your UEI for scores based on your award history.
Description (excerpt)
This technology from scientists at Los Alamos National Laboratory represents a novel platform for improving the safety and effectiveness of therapeutic gas-based treatments by enabling controlled, localized delivery at the site of disease. By addressing longstanding challenges associated with systemic exposure and dosing precision, the platform enhances the clinical viability of gas therapies across high-value markets such as oncology, cardiovascular care, and regenerative medicine. In addition, the inclusion of a complementary predictive modeling capability supports treatment optimization and development efficiency, reducing technical risk and accelerating translation. Together, these capabilities position the technology as a differentiated and scalable solution that can unlock new commercial opportunities in areas where gas-based therapeutics have shown promise but faced delivery limitations. The Opportunity: Therapeutic gases have demonstrated meaningful biological effects across oncology, cardiovascular disease, neuroprotection and regenerative medicine, yet their clinical adoption has been limited by a fundamental challenge: safe, controlled and localized delivery. Existing approaches often result in rapid release, systemic exposure or narrow therapeutic windows, creating safety, regulatory and development barriers. The Clathrate Therapeutics Platform addresses this unmet need by positioning gas-based therapies as programmable, targetable and commercially viable treatment modalities. By enabling more precise control over where and how therapeutic gases are delivered, the platform has the potential to unlock new product categories, enhance combination treatment strategies and accelerate translation of gas-based therapeutics into high-value clinical markets. How it Works: The Clathrate Therapeutics Platform uses a proprietary, controlled-release system designed to localize therapeutic gases at the intended treatment site rather than allowing them to disperse systemically. This technology temporarily stabilizes the gas within a biocompatible structure that gradually releases it under physiological conditions, enabling sustained and targeted exposure. This controlled release approach is designed to support therapeutic concentrations where needed while limiting circulating levels elsewhere in the body. An integrated computational modeling capability further supports optimization of dosing profiles and treatment parameters, helping guide development decisio …